Archive: September, 2010

• Movectro (oral cladribine) Approved in AUSTRALIA

  Merck KGaA announced that the Australian Therapeutic Goods Administration (TGA) has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS). Cladribine Tablets will be registered [...]

  • Caroline says: The Australian Therapeutic Goods Association (TGA) has approved oral cladribine for patients with RRMS. Trade name "Movectro" -- this follows the Russian approval in July 2010...a US FDA decision is expected towards the end of 2010.
     
  • Related Links:
  • http://www.medicalnewstoday.com/articles/200046.php…
  
  

  • Study finds that most neurologists plan to prescribe oral MS drugs when approved this year

    Majestic Research Study Indicates that Neurologists’ Apprehension Regarding Side Effects Won’t Stop Them from Prescribing New Oral MS Drugs, but Concerns Will Likely Relegate Their Use to [...]

    • Caroline says: A recent study showed that 84% of neurologists polled plan to prescribe Novartis' Gilenia (FTY-720) and Serono's cladribine for some of their RRMS patients when they are approved later this year (end of September for Gilenia, later in 2010 for cladribine). However, until safety concerns for both drugs are resolved, they will most likely be prescribed as second-line and third-line agents, despite the fact that their FDA approval will probably be as first-line agents.
       
    • Related Links:
    • http://www.fiercepharma.com/story/tevas-oral-laquinimod-ms-gets-fast-tracked/200…
    
    

    • JK Rowling Gives £10 Million For MS Clinic

      The author JK Rowling has donated £10m to set up a clinic to research treatments for multiple sclerosis, the degenerative disease that killed her mother at the [...]

      • Caroline says: I knew there was a reason I continue to be such a big Harry Potter fan. Author JK Rowling has been a long time supporter of the UK MS Society, and her latest £10 million gift to set up a clinic to research treatments there for MS and other neurodegenerative diseases represents the largest single gift the University of Edinburgh has ever received. Cheers to you, JK Rowling.
         
      • Related Links:
      • http://www.guardian.co.uk/books/2010/aug/31/jk-rowling-donation-multiple-scleros…
      
      

      • Sanofi’s Teriflunomide Shows Promise for RRMS

        Sanofi-aventis (NYSE:SNY) recently announced clinical success with teriflunomide, the investigational drug it is developing for the treatment of relapsing multiple sclerosis (RMS). This announcement followed a 2-year [...]

        • Caroline says: The oral market for MS continues to widen...Sanofi's teriflunomide for RRMS announced positive results from TEMSO a 2-year trial v. placebo. Full results will be presented at ECTRIMS this year (Oct 2010).
           
        • Related Links:
        • http://starglobaltribune.com/2010/multiple-sclerosis-new-teriflunomide-treatment…
        
        
        Next Entries »